XPEV enters its August 27 earnings print with short sellers rebuilding aggressively and the borrow market at its tightest in months — a combination that sets up a charged tape into tomorrow's release.
The most striking move this week is in short positioning. Estimated short interest jumped 14% in a single session on August 25, rising to roughly 46 million shares — the highest level since late July. That one-day surge follows a week-over-week gain of 13%, reversing a month-long decline that had briefly brought shorts back toward 40 million shares. The speed of the rebuild is notable: shorts dropped steadily through mid-August and then snapped back in two days, concentrated right on the eve of results. The ORTEX short score reflects this pressure, climbing to 66.1 on August 25 from 63.2 the prior day — its highest reading in the trailing window and ranking in the bottom 9th percentile of the universe on that measure.
The borrow market has tightened in lockstep with the short rebuild. Availability has fallen to just 23% — meaning only roughly one share remains available to borrow for every three already lent out. That is down from 35% a week ago and matches the compressed levels last seen on August 10, when the lending pool briefly hit its annual floor. Cost to borrow, while still modest at 1.44%, is up 32% on the week and has nearly doubled over the past month. Borrow conditions remain manageable in absolute terms, but the direction of travel — availability tightening, short interest rising sharply, borrow cost climbing — points to renewed demand for short exposure that is running faster than supply can meet. Options traders are not sending the same alarm: the put/call ratio of 0.34 is barely above its 20-day average of 0.34, and well below the 52-week high of 0.72. Call volume still dominates puts, consistent with the bullish lean noted in prior coverage ahead of the August 24 print.
The Street is cautious but divided. Barclays trimmed its target to $14 from $15 yesterday while holding its Underweight rating — the third downward revision from that firm this year. JP Morgan moved in the opposite direction on conviction, cutting its target to $24 from $27 but maintaining Overweight. Those two actions capture the bull-bear split: bears point to persistent execution risk in a brutally competitive Chinese EV market, while bulls see the stock, trading at $11.60, as offering meaningful upside to even the more conservative bull targets. The mean analyst price target of $140 appears to be a data artefact — likely reflecting stale or aggregated inputs from a different listing context — and should not be relied upon. Valuation tells a similarly complicated story: the EV/EBITDA multiple has compressed about 10% over the past month to roughly 30x, while the P/E remains elevated at 121x, reflecting a stock that is cheap on asset value but still pricing in a recovery that has not fully arrived. The EPS surprise factor score sits in the 99th percentile, suggesting the company has consistently beaten estimates — but near-term EPS momentum scores rank in the 2nd and 4th percentiles, meaning analysts have been cutting numbers fast and the beat bar keeps moving lower.
The price action since the August 24 earnings event illustrates the difficulty. XPEV fell 4.8% the day after that release, recovered modestly, and is now up 4% on Tuesday. But the stock is still down 6% over the past month. Peers have been mixed on the week: NIO is down 1.8%, while LI gained 1.2% and TSLA added 4%. XPEV's isolation from the broader EV recovery that propelled peers through August sharpens the stakes for tomorrow's print.
The question for August 27 is whether the earnings release can shift the narrative from one of persistent underperformance to one of genuine operational inflection — and whether shorts who rebuilt so quickly into the release decide to hold through the result or cover into any initial reaction.
See the live data behind this article on ORTEX.
Open XPEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
